StreetAlpha.app
Home › Stocks › ONCY

Oncolytics Biotech Inc (ONCY)

Healthcare
$0.38
▲ +12.53%
LAST CLOSE · NOV 17

Oncolytics Biotech develops pelareorep, an experimental intravenous cancer therapy for gastrointestinal tumors. It last closed at $0.38 on Nov 17, up 12.53% on the day.

AI Auto Pilots
Is ONCY in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2024
Results
Net income
−CAD 31.7M
Balance sheet
Cash & equivalents
CAD 15.9M
At Dec 31
Shareholder equity
CAD 6.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: −CAD 22.5M−CAD 22.5MFY2020FY2021: −CAD 26.3M−CAD 26.3MFY2021FY2022: −CAD 24.8M−CAD 24.8MFY2022FY2023: −CAD 27.8M−CAD 27.8MFY2023FY2024: −CAD 31.7M−CAD 31.7MFY2024

From ONCY's SEC filings, latest 10-Q for the period ending Dec 31, 2024 (filed Nov 13). Figures are in CAD. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated ONCY in the past 90 days.
Average 12-month target
No price targets on ONCY in the past 90 days.
Latest rating changes
HC Wainwright & Co.Target lowered
Aug 19Buy$10 → $5
HC Wainwright & Co.Reiterated
May 26Buy$10
DateFirmActionRatingPrice target
Aug 19HC Wainwright & Co.Target loweredBuy$10 → $5
May 26HC Wainwright & Co.ReiteratedBuy$10
Loading…

Technical Analysis

ONCY · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 11% below its 20 day and 46% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38), near oversold. The nearest support is the swing low (Nov 3) at $0.38, and the nearest resistance the Pivot R1 at $0.40.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityHigh, 12.2%/day
Key levels
$1.3052 week high+242.1%
$0.82200 day average+115.8%
$0.70100 day average+84.2%
$0.5650 day average+47.4%
$0.46Swing high (Nov 9)+21.1%
$0.4320 day average+13.2%
$0.40Pivot R1+5.3%
$0.38Swing low (Nov 3)+0.0%
$0.38Last close
$0.37Pivot−2.6%
$0.35Pivot S1−7.9%
$0.3352 week low−13.2%
Indicators
RSI (14)37.75Weak, oversold below 30Neutral
MACD-0.05Below its signal lineBearish
Stochastic20.7Middle of its rangeNeutral
ADX (14)44.1Strong downtrend
Williams %R-61.2Oversold below −80, overbought above −20Neutral
CCI (20)-103.0Oversold below −100, overbought above 100Oversold
Rate of change−1.9%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ONCY

What happened before

See how ONCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ONCY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ONCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ONCY in the last 90 days.

Loading…

See today’s whale options flow across the market →

ONCY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲28 buying vs 24 selling
  • ▼Held by funds -0.7 pts
  • ▲Funds holding +2
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7775+2.7%
In funds' top 1000–
Held by funds2.4%3.1%−0.7 pts
New / increased10 / 1872 / 0−61.1%
Reduced / sold out15 / 91 / 1+1100.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ONCY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONCY is in one of them and how their past ONCY trades turned out.

ONCY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ONCY in an article yet. Here's the latest on the wider market.

About Oncolytics Biotech

Oncolytics Biotech is a biopharmaceutical company based in San Diego, California. It is developing pelareorep, an experimental cancer therapy given intravenously that is made from a common virus that does not cause disease. The company is testing pelareorep alone and with other cancer treatments, mainly for gastrointestinal cancers, and plans to partner with larger drug companies. Its intended customers are cancer patients and the doctors who treat them.

Headquarters
San Diego, CA
Founded
1998